This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2010 Apr;45(4):511-2.

doi: 10.3109/00365521003628335.

Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma

Emmanouil Sinakos, Ioannis Dedes, Lavrentis Papalavrentios, Antonios Drevelegas, Evangelos Akriviadis

PMID: 20113152
DOI: 10.3109/00365521003628335

Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma

Emmanouil Sinakos et al. Scand J Gastroenterol. 2010 Apr.

. 2010 Apr;45(4):511-2.

doi: 10.3109/00365521003628335.

Authors

Emmanouil Sinakos, Ioannis Dedes, Lavrentis Papalavrentios, Antonios Drevelegas, Evangelos Akriviadis

PMID: 20113152
DOI: 10.3109/00365521003628335

No abstract available

PubMed Disclaimer

Similar articles

Major achievements in hepatocellular carcinoma.
Bruix J, Llovet JM. Bruix J, et al. Lancet. 2009 Feb 21;373(9664):614-6. doi: 10.1016/S0140-6736(09)60381-0. Lancet. 2009. PMID: 19231618 No abstract available.
TACE with or without systemic therapy?
Dufour JF. Dufour JF. J Hepatol. 2012 Jun;56(6):1224-5. doi: 10.1016/j.jhep.2012.02.011. Epub 2012 Mar 5. J Hepatol. 2012. PMID: 22402292 No abstract available.
Clinical value of continuous administration of sorafenib in combination with modified transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Huang YH, Chen W, Li JP, Chen B, Yang JY. Huang YH, et al. Chin Med J (Engl). 2013 Jan;126(2):385-6. Chin Med J (Engl). 2013. PMID: 23324295 No abstract available.
[The treatment of hepatocellular carcinoma. New developments].
Kuiken SD, van Delden OM, Richel DJ, Jansen PL. Kuiken SD, et al. Ned Tijdschr Geneeskd. 2009 Apr 4;153(14):668-72. Ned Tijdschr Geneeskd. 2009. PMID: 19425326 Review. Dutch. No abstract available.
Review article: the management of hepatocellular carcinoma.
Cabrera R, Nelson DR. Cabrera R, et al. Aliment Pharmacol Ther. 2010 Feb 15;31(4):461-76. doi: 10.1111/j.1365-2036.2009.04200.x. Epub 2009 Nov 19. Aliment Pharmacol Ther. 2010. PMID: 19925500 Review.

See all similar articles

Cited by

The role of sorafenib in downsizing hepatocellular carcinoma prior to liver transplantation and in treating tumor recurrence.
Sinakos E, Selvaggi G, Papalavrentios L, Tzakis A, Akriviadis E. Sinakos E, et al. Ann Gastroenterol. 2011;24(3):228-230. Ann Gastroenterol. 2011. PMID: 24713719 Free PMC article.
Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.
Dufour JF, Hoppe H, Heim MH, Helbling B, Maurhofer O, Szucs-Farkas Z, Kickuth R, Borner M, Candinas D, Saar B. Dufour JF, et al. Oncologist. 2010;15(11):1198-204. doi: 10.1634/theoncologist.2010-0180. Epub 2010 Oct 29. Oncologist. 2010. PMID: 21036880 Free PMC article. Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
Medical
- MedlinePlus Health Information